Koninklijke Philips (NYSE:PHG – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Profitability
This table compares Koninklijke Philips and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Koninklijke Philips | 6.30% | 14.38% | 5.96% |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
Earnings and Valuation
This table compares Koninklijke Philips and Beta Bionics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Koninklijke Philips | $20.17 billion | 1.26 | $1.01 billion | $1.36 | 19.04 |
| Beta Bionics | $100.25 million | 8.72 | -$73.20 million | ($1.65) | -11.77 |
Koninklijke Philips has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Koninklijke Philips and Beta Bionics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Koninklijke Philips | 0 | 5 | 0 | 0 | 2.00 |
| Beta Bionics | 1 | 4 | 7 | 0 | 2.50 |
Beta Bionics has a consensus price target of $20.10, indicating a potential upside of 3.50%. Given Beta Bionics’ stronger consensus rating and higher probable upside, analysts plainly believe Beta Bionics is more favorable than Koninklijke Philips.
Volatility & Risk
Koninklijke Philips has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.37, suggesting that its share price is 237% more volatile than the S&P 500.
Institutional and Insider Ownership
13.7% of Koninklijke Philips shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Koninklijke Philips beats Beta Bionics on 8 of the 14 factors compared between the two stocks.
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease. In addition, the company offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. Further, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. The company has strategic partnership agreements with TriHealth, Northwell, and Atrium Health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.
